IW-601 / ImmuneWalk Therapeutics - LARVOL DELTA

IW-601, a First in Class Antibody Targeting Myeloid Cell Trafficking Demonstrates Safety, PK and PD Mechanistic Validation in a Phase I Clinical Trial (EULAR 2026) - "These results support continued development of this first in class antibody in indications driven by neutrophil and monocyte activity. A Phase 1b study in Behcet’s Disease is planned for 2026."

Clinical • First-in-human • P1 data • Immunology • Inflammation • Metabolic Dysfunction-Associated Steatohepatitis • Rare Diseases • CXCL8 • IL1B • IL2 • IL4 • IL6 • TNFA

IW-601, a first-in-class monoclonal antibody targeting myeloid cells is safe and well tolerated. Pharmacodynamic assessments provide mechanistic validation; Results from IW-601-001 a first-in-human Phase 1 Single Ascending Doses study (EULAR 2025) - "Single ascending doses of subcutaneous IW-601 up to a dose of 10 mg/kg were safe and well tolerated in healthy subjects. The PK profile shows dose-proportionality and long half-life which is expected to allow subcutaneous dosing once every 3-4 weeks. In vivo PD data provide mechanistic validation for IW-601."

P1 data • PK/PD data • Dermatology • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis